Graft Versus Host Disease (GVHD) of the Gastrointestinal (GI) Tract: Diagnostic Yield of Upper Versus Lower Endoscopic Biopsies and their Clinical Application: 1782Miller, EthanFuntowicz, LucianaDe Petris, GiovanniSlack, JamesLeis, JoseWindgassen, Elizabeth...
New Test Could Guide More Precise Treatment of GVHD Palliative Care Issues in Gynecologic CancerNewsletter Stay up to date on the most recent and practice-changing oncology data Subscribe Now! Related Videos Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC Data From a...
“Vedolizumab was more effective than placebo for the prevention of lower GI GVHD after unrelated allogeneic transplant when added to a standard calcineurin inhibitor–based GVHD platform,” said Yi-Bin Chen, MD, director of the Hematopoietic Cell Transplant & Cell Therapy Program and the Allen...
Introduction Acute graft versus host disease may affect the gastrointestinal track (aGI-GvHD) in up to 60% of haematopoetic stem cell transplant (HSCT) recipients who develop GvHD resulting in significant morbidity. Half of these patients will develop steroid refractory disease which is associated ...
The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.
Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease Acute graft-versus-host disease (GVHD) is a frequent and potentially life-threatening complication following allogeneic hematopoietic cell transplantation ... R Olle,S Behnam - 《Stem Cells》 被...
Finally, although Treg infiltration density was not significantly higher in severe GvHD, it again correlated with the abundance of CD8 T cells (Figure 2F), as observed before. Altogether, these differences suggest that CD8 T cells might play a role in disease progression; indeed, their enrichment...
Bhlhe40+ GM-CSF+ CD4+ T cells constitute a colitogenic T-cell population that promotes indirect alloantigen presentation and pathological damage within the GI tract, positioning GM-CSF as a key regulator of GVHD in the colon and a potential therapeutic target for amelioration of this disease. ...
Recently, ruxolitinib has been approved by the Food and Drug Administration in the US for therapy of steroid refractory acute GVHD. Main severe side effects of ruxolitinib therapy, particularly in combination with other immunosuppressive therapies, are prolonged pancytopenia attended by severe infections ...
美国NCT数据库提供标题为Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD的临床试验登记信息,包括基本信息,试验详情,试验设计,试验分组,治疗终点,招募标准,联系人与地点等.